Sildenafil therapy in thalassemia patients with Doppler-defined risk of pulmonary hypertension
Open Access
- 12 April 2013
- journal article
- research article
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 98 (9) , 1359-1367
Abstract
Pulmonary hypertension is a common but often overlooked complication associated with thalassemia syndromes. There are limited data on the safety and efficacy of selective pulmonary vasodilators in this at-risk population. We, therefore, designed a 12-week, open-label, phase 1/2, pilot-scale, proof-of-principle trial of sildenafil therapy in 10 patients with β-thalassemia and at increased risk of pulmonary hypertension based on an elevated tricuspid regurgitant jet velocity >2.5 m/s on Doppler-echocardiography. Variables compared at baseline and after 12 weeks of sildenafil treatment included Doppler-echocardiographic parameters, 6-minute walked distance, Borg Dyspnea Score, New York Heart Association functional class, pulmonary function, and laboratory parameters. Treatment with sildenafil resulted in a significant decrease in tricuspid regurgitant jet velocity by 13.3% (3.0±0.7 versus 2.6±0.5 m/s, P=0.04), improved left ventricular end systolic/diastolic volume, and a trend towards a improved New York Heart Association functional class. No significant change in 6-minute walked distance was noted. Sildenafil was well tolerated, although minor expected adverse events were commonly reported. The total dose of sildenafil (mg) was strongly correlated with percent change in nitric oxide metabolite concentration in the plasma (ρ=0.80, P=0.01). There were also significant increases in plasma and erythrocyte arginine concentrations. Our study suggests that sildenafil is safe and may improve pulmonary hemodynamics in patients at risk of pulmonary hypertension; however, it was not demonstrated to improve the distance walked in 6 minutes. Clinical trials are needed to identify the best treatment strategy for pulmonary hypertension in patients with β-thalassemia. (clinicaltrials.gov identifier: NCT00872170)Keywords
This publication has 54 references indexed in Scilit:
- Mortality in Adults With Sickle Cell Disease and Pulmonary HypertensionJAMA, 2012
- TRV: A physiological biomarker in sickle cell diseasePediatric Blood & Cancer, 2011
- Risk factors and mortality associated with an elevated tricuspid regurgitant jet velocity measured by Doppler-echocardiography in thalassemia: a Thalassemia Clinical Research Network reportBlood, 2011
- Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacityBlood, 2011
- Elevated liver iron concentration is a marker of increased morbidity in patients with thalassemia intermediaHaematologica, 2011
- Pulmonary hypertension and NO in sickle cellBlood, 2010
- Diminished Global Arginine Bioavailability and Increased Arginine Catabolism as Metabolic Profile of Increased Cardiovascular RiskJACC, 2009
- The effects of sildenafil and acetazolamide on breathing efficiency and ventilatory control during hypoxic exerciseEuropean Journal of Applied Physiology, 2009
- Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobinBlood, 2007
- Splenectomy: a strong risk factor for pulmonary hypertension in patients with thalassaemiaHeart, 2006